Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer
This is a multicentric prospective non-randomized phase II trial, with two independent arms: one for patients with RAS mutation and one for patients with BRAFV600E mutation.
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
DRUG: Trametinib|DRUG: Dabrafenib|RADIATION: 131I|DRUG: rhTSH
Objective Response Rate (ORR), Propotion of patients with a best overall response of Complete Response (CR) or a Partial Response (PR), Evaluated 6 months after the first dose of trametinib or trametinib and dabrafenib followed by RAI treatment in each arms
This is a multicentric prospective non-randomized phase II trial, with two independent arms: one for patients with RAS mutation and one for patients with BRAFV600E mutation.